Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.
Vaccination with P13, a peptide mimotope of the cryptococcal capsular polysaccharide glucuronoxylomannan (GXM), has been shown to confer protection against a subsequent lethal Cryptococcus neoformans challenge. In this study, we sought to investigate whether P13-based vaccines could be effective in an already-established infection. To address this question, we developed a systemic chronic cryptococcal infection model. We vaccinated chronically infected mice with P13-protein conjugates and monitored their survival. Compared to the controls, the conjugates prolonged the survival of chronically infected mice. The degree of protection was a function of the mouse strain (BALB/c or C57BL/6), the carrier protein (tetanus toxoid or diphtheria toxoid), and the route of infection (intraperitoneal or intravenous). Serum GXM levels were correlated with the day of death, but the correlation was driven by the carrier protein and mouse strain. The passive transfer of heat-treated sera from P13 conjugate-vaccinated mice conferred protection to naïve BALB/c mice, indicating that antibody immunity could contribute to protection. The measurement of peripheral blood cytokine (gamma interferon [IFN-gamma], interleukin-10 [IL-10], and IL-6) gene expression showed that P13 conjugate-vaccinated BALB/c and C57BL/6 mice mounted a strong Th2 (IL-10)-like response relative to the Th1 (IFN-gamma)-like response, with the degree depending on the mouse strain and carrier protein. Taken together, our data suggest that a vaccine could hold promise in the setting of chronic cryptococcosis, and that vaccine efficacy could depend on immunomodulation and augmentation of the natural immune response of the host.
Datta
Kausik
K
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Lees
Andrew
A
Pirofski
Liise-anne
LA
D000818:Animals; D000908:Antibodies, Fungal / Q000097:blood; D002908:Chronic Disease; D003453:Cryptococcosis / Q000276:immunology / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control; D003455:Cryptococcus neoformans / Q000276:immunology / Q000472:pathogenicity; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D005657:Fungal Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018716:Molecular Mimicry; D010455:Peptides / Q000737:chemistry / Q000276:immunology; D011134:Polysaccharides / Q000097:blood / Q000737:chemistry / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*
D000908:Antibodies, Fungal; D016207:Cytokines; D005657:Fungal Vaccines; D010455:Peptides; D011134:Polysaccharides; D018074:Vaccines, Conjugate; C014426:cryptococcal polysaccharide; C027478:glucuronoxylomannan